At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

May 26, 2015
Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment by European Regulators

May 5, 2015
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates

View all »Events & Presentations

May 5, 2015 at 5:00 PM ET
Amicus 1Q Results Conference Call and Webcast

Mar 19, 2015 at 8:00 AM ET
Fabry Monotherapy Global Regulatory Update

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy